GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
GSK plc is pushing for wider access to bepirovirsen in China, locking in an exclusive deal with Chia Tai Tianqing Pharmaceutical, part of Sino Biopharmaceutical. With this move, the British pharma giant aims to turn its late-stage hepatitis B candidate into a serious growth engine. CTTQ is set to manage import, distribution, hospital access, and promotion across mainland China. GSK, for its part, keeps a grip on regulatory and medical strategy. Timing’s key here. Bepirovirsen is on the investor radar as GSK pushes to move past its traditional vaccine and HIV drug business, aiming to top £40 billion in yearly sales by 2031—a goal it stuck with after posting £7.6 billion for the first quarter. Last month, Chief Executive Luke